[1] Chamot A M, Benhamou C L, Kahn M F,et al.Acne-pustulosis-hyperosis-osteitis syndrome.Results of a national survey.85 cases[J].Rev Rhum Mal Osteoartic,1987,54(3):187-196. [2] Hurtado N M, Chollet M S, Chapeton D, et al.Genetie susceptibility factors in a cohort of 38 patients with SAPHO syndrome:a study of PSTPIP2,NOD2,and LPIN2 genes[J].J Rheumatol, 2010, 37(2):401-409. [3] Cassel S L, Janczy J R, Bing X, et al.Inflammasome-independent IL-1β mediates autoinflammatory diseases in Pstpip2-deficient mice[J].Proc Natl Acad Sci U S A, 2014, 111(3): 1072-1077. [4] Zimmermann P, Curtis N. The role of cutibacterum acnes in auto-inflammatory bone disorders[J]. Eur Pediatr,2019,178(1):89-95. [5] Kishimoto M,Taniguchi Y,Tsuji S,et al.SAPHO syndrome and pustulotic arthro-osteitis[J].Mod Rheumatol,2022,32(4):665-674. [6] Nguyen M T, Borchers A, Selmi C,et al.The SAPHO syndrome[J].Semin Arthritis Rheum, 2012,42(3):254-265. [7] Zimmermann P, Curtis N.Synovitis,acne,pustulosis,hyperostosis,and osteitis (SAPHO) syndrome-a challenging diagnosis not to be missed[J].J Infect,2016,72(7):S106-S114. [8] Hurtado N M,Chollet M S,Chapeton D,et al.Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome:a study of PSTPIP2,NOD2,and LPIN2 genes[J].J Rheumatol, 2010, 37(2):401-409. [9] Rukavina I.SAPHO syndrome:a review[J].J Child Orthop,2015,9(1):19-27. [10] Berthetot J M, Corvec S,Hayem G, SAPHO,autophagy,IL-1,FoxO1,and Propionibacterium (Cutibacterium) acnes [J]. Joint Bone Spine,2018,85(2):171-176. [11] Govoni M,Colina M,Massara A,et al.SAPHO syndrome and infections[J].Autoimmun Rev, 2009, 8(3):256-259. [12] Sonozaki H, Mitsui H, Miyanaga Y, et al.Clinical features of 53 cases with pustulotic arthro- osteitis[J].Ann Rheum Dis,1981,40(6):547-553. [13] 刘记存,陈 勇,崔建岭.SAPHO综合征的影像表现[J].中国医学影像技术,2011,27(8):1684-1687. [14] Depasquale R,Kumar N,Lalam R K,et al.SAPHO:what radiologis should know[J].Clin Radiol, 2012,67(3):195-206. [15] Earwaker J W S,Cotten A.SAPHO:syndrome of concept imaging findings[J].Skeletal Radiol, 2003,32(6):311-327. [16] 石静艺,迪丽努尔,阿不都热依木,等.SAPHO综合征14例临床特征与治疗[J].中国皮肤性病学杂志,2023,37(2):168-173. [17] Wendling D,Aubin F,Verhoeven F,et al.IL-23/Th17 targeted therapies in SAPHO syndrome.A case series[J].Joint Bone Spine,2017,84(6):733-735. [18] Wekell P,Bjornsdottir H,Bjorkman L,et al.Neutrophils form patients with SAPHO syndrome show no signs of aberrant NADPH oxidase-dependent production of intracellular reactive oxygen species [J].Rheumatology,2016,55(8):1489-1498. [19] Daoussis D,Konstantopoulou G,Kraniotis P,et al.Biologics in SAPHO syndrome:a systematic review[J].Semin Arthritis Rheum,2019,48(4):618-625. [20] 乌日嘎, 韩建文, 吕新翔,等.SAPHO综合征81例临床分析[J].中国皮肤性病学杂志,2023,37(1):64-69. [21] Wendling D,Aubin F,Verhoeven F,et al.IL-23/Th17 targeted therapies in SAPHO syndrome:a case series[J].Joint Bone Spine,2017,84(6):733-735. [22] Xu D,Liu X,Lu C,et al.Reduction of peripheral natural killer cells in patient with SAPHO syndrome [J].Clin Exp Rheumatol,2019,37(1):12-18. [23] Zhang S,Li C, Zhang S,et al.Serum levels of proinflammatory,anti-inflammatorsyndy cytokines,and RANKL/OPG in synovitis,acne,pustulosis,hyperotosis,and osteitis(SAPHO),syndrome [J].Mod Rheumatol,2019,29(3):523-530. [24] Labranche T P,Jesson M I,Radi Z A,et al.JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production [J].Arthritis Rheum, 2012,64(11):3531-3542. [25] Li C, Li Z,Cao Y,et al.Tofacitinib for the treatment of nail lesions and palmoplantar pustulosis in synovitis,acne,pustulosis,hyperotosis,and osteitis syndrome[J].JAMA Dermatol, 2021,157(1):74-78. [26] 蒋 萍,曾鹏慧,田消消,等.JAK抑制剂在SAPHO综合征中的应用[J].中国皮肤性病学杂志,2024,38(6):699-704.
PDF(918 KB)
